Rudy Li
Stock Analyst at Wolfe Research
(4.97)
# 18
Out of 5,150 analysts
39
Total ratings
72.97%
Success rate
88.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rudy Li
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | $40 | $26.70 | +49.81% | 5 | Feb 24, 2026 | |
| ALKS Alkermes | Initiates: Outperform | $45 | $29.28 | +53.69% | 1 | Feb 24, 2026 | |
| AXSM Axsome Therapeutics | Initiates: Outperform | $230 | $164.08 | +40.18% | 1 | Feb 24, 2026 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $60 | $43.05 | +39.37% | 5 | Feb 24, 2026 | |
| STOK Stoke Therapeutics | Initiates: Outperform | $40 | $34.42 | +16.21% | 5 | Feb 24, 2026 | |
| QURE uniQure | Initiates: Peer Perform | n/a | $9.04 | - | 1 | Feb 24, 2026 | |
| DNLI Denali Therapeutics | Initiates: Peer Perform | n/a | $20.37 | - | 1 | Feb 24, 2026 | |
| PRAX Praxis Precision Medicines | Initiates: Outperform | $500 | $325.11 | +53.79% | 4 | Feb 24, 2026 | |
| NBIX Neurocrine Biosciences | Initiates: Outperform | $160 | $133.44 | +19.90% | 1 | Feb 24, 2026 | |
| DFTX Definium Therapeutics | Initiates: Outperform | $25 | $17.76 | +40.77% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $23.39 | +41.09% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $79.31 | +0.87% | 3 | Jan 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3 | $1.17 | +156.41% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $21.43 | -30.00% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2 | $0.24 | +718.67% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 | $9.86 | +82.56% | 7 | Aug 28, 2025 |
Centessa Pharmaceuticals
Feb 24, 2026
Initiates: Outperform
Price Target: $40
Current: $26.70
Upside: +49.81%
Alkermes
Feb 24, 2026
Initiates: Outperform
Price Target: $45
Current: $29.28
Upside: +53.69%
Axsome Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $230
Current: $164.08
Upside: +40.18%
Xenon Pharmaceuticals
Feb 24, 2026
Initiates: Outperform
Price Target: $60
Current: $43.05
Upside: +39.37%
Stoke Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $40
Current: $34.42
Upside: +16.21%
uniQure
Feb 24, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $9.04
Upside: -
Denali Therapeutics
Feb 24, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $20.37
Upside: -
Praxis Precision Medicines
Feb 24, 2026
Initiates: Outperform
Price Target: $500
Current: $325.11
Upside: +53.79%
Neurocrine Biosciences
Feb 24, 2026
Initiates: Outperform
Price Target: $160
Current: $133.44
Upside: +19.90%
Definium Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $25
Current: $17.76
Upside: +40.77%
Feb 24, 2026
Initiates: Outperform
Price Target: $33
Current: $23.39
Upside: +41.09%
Jan 2, 2026
Maintains: Buy
Price Target: $80
Current: $79.31
Upside: +0.87%
Sep 29, 2025
Initiates: Buy
Price Target: $3
Current: $1.17
Upside: +156.41%
Sep 29, 2025
Initiates: Buy
Price Target: $15
Current: $21.43
Upside: -30.00%
Sep 29, 2025
Initiates: Buy
Price Target: $2
Current: $0.24
Upside: +718.67%
Aug 28, 2025
Maintains: Buy
Price Target: $18
Current: $9.86
Upside: +82.56%